MediSense preparing for Precision QID glucose monitor launch in U.S..
This article was originally published in The Gray Sheet
MEDISENSE PRECISION QID THIRD GENERATION GLUCOSE MONITORING SYSTEM will begin U.S. shipments "at or around the end of this quarter," MediSense Chairman and CEO Robert Coleman, PhD, said at a May 16 session of the Alex. Brown & Sons health care seminar in Baltimore. Both the home glucose monitoring device and attendant disposable strips were cleared by FDA on March 23.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.